Additionally, the 36-month beta value for MIST is 1.77. There are mixed opinions on the stock, with 3 analysts rating it as a “buy,” 2 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for MIST is 50.45M and currently, short sellers hold a 0.90% ratio of that float. The average trading volume of MIST on November 21, 2024 was 247.91K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
MIST) stock’s latest price update
Milestone Pharmaceuticals Inc (NASDAQ: MIST) has experienced a rise in its stock price by 6.90 compared to its previous closing price of 1.74. However, the company has seen a gain of 1.09% in its stock price over the last five trading days. zacks.com reported 2024-11-19 that Milestone Pharmaceuticals Inc. (MIST) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, MIST’s 50-day simple moving average broke out above its 200-day moving average; this is known as a “golden cross.
MIST’s Market Performance
Milestone Pharmaceuticals Inc (MIST) has seen a 1.09% rise in stock performance for the week, with a 26.53% gain in the past month and a 29.17% surge in the past quarter. The volatility ratio for the week is 7.18%, and the volatility levels for the past 30 days are at 8.27% for MIST. The simple moving average for the past 20 days is 11.61% for MIST’s stock, with a 19.43% simple moving average for the past 200 days.
Analysts’ Opinion of MIST
Many brokerage firms have already submitted their reports for MIST stocks, with Rodman & Renshaw repeating the rating for MIST by listing it as a “Buy.” The predicted price for MIST in the upcoming period, according to Rodman & Renshaw is $9 based on the research report published on August 22, 2024 of the current year 2024.
Jefferies, on the other hand, stated in their research note that they expect to see MIST reach a price target of $4, previously predicting the price at $8. The rating they have provided for MIST stocks is “Hold” according to the report published on June 20th, 2023.
Piper Sandler gave a rating of “Overweight” to MIST, setting the target price at $10 in the report published on April 22nd of the previous year.
MIST Trading at 18.57% from the 50-Day Moving Average
After a stumble in the market that brought MIST to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -47.16% of loss for the given period.
Volatility was left at 8.27%, however, over the last 30 days, the volatility rate increased by 7.18%, as shares surge +26.53% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +28.28% upper at present.
During the last 5 trading sessions, MIST rose by +1.09%, which changed the moving average for the period of 200-days by +18.10% in comparison to the 20-day moving average, which settled at $1.6665. In addition, Milestone Pharmaceuticals Inc saw 11.38% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for MIST
Current profitability levels for the company are sitting at:
- 50.34 for the present operating margin
- 1.68 for the gross margin
The net margin for Milestone Pharmaceuticals Inc stands at 49.27. The total capital return value is set at -0.56. Equity return is now at value -162.87, with -50.37 for asset returns.
Based on Milestone Pharmaceuticals Inc (MIST), the company’s capital structure generated 0.69 points at debt to capital in total, while cash flow to debt ratio is standing at -0.59. The debt to equity ratio resting at 2.21. The interest coverage ratio of the stock is -12.42.
Currently, EBITDA for the company is -56.84 million with net debt to EBITDA at -1.06. When we switch over and look at the enterprise to sales, we see a ratio of -161.76. The receivables turnover for the company is -0.72for trailing twelve months and the total asset turnover is -0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 15.40.
Conclusion
In conclusion, Milestone Pharmaceuticals Inc (MIST) has seen better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
